...EPO), is in Phase I testing. Lundbeck is co-developing the therapies with Bayer AG and Warren Pharmaceuticals Inc....
...Toronto Western Research Institute , Toronto, Ontario, Canada University of Toronto , Toronto, Ontario, Canada Warren Pharmaceuticals Inc....

...issues, the findings could add a new indication for tissue-protecting erythropoietin mimetics being developed by Warren Pharmaceuticals Inc....
...Center , Omaha, Ne.   University of Toronto , Toronto, Ontario, Canada   Warren Pharmaceuticals Inc....

...At least six companies market EPO or EPO analogs to treat anemia. Shire plc and Warren Pharmaceuticals Inc....

...to Lu AA24493 for CNS-related indications from Warren in 2002 (see BioCentury, Feb. 25, 2002). Warren Pharmaceuticals Inc....

...to Lu AA24493 for CNS-related indications from Warren in 2002 (see BioCentury, Feb. 25, 2002). Warren Pharmaceuticals Inc....

...a Phase I study in acute ischemic stroke in October. LUN in-licensed the compound from Warren Pharmaceuticals Inc....

...the central nervous system from Warren under a 2002 agreement (see BioCentury, Feb. 25, 2002). Warren Pharmaceuticals Inc....

...Europe in the first half of 2007. Shire Pharmaceuticals Group plc (LSE:SHP; SHPGY), Basingstoke, U.K. Warren Pharmaceuticals Inc....

...to stimulate red blood cells has resulted in several blockbuster drugs to treat anemia. But Warren Pharmaceuticals Inc....

...did not show any hematopoietic activity in culture or in dosing in different animal species. Warren Pharmaceuticals Inc....